NASDAQ:SGMO Sangamo Therapeutics (SGMO) Stock Price, News & Analysis $0.46 +0.01 (+1.24%) Closing price 04:00 PM EasternExtended Trading$0.46 +0.00 (+0.94%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sangamo Therapeutics Stock (NASDAQ:SGMO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sangamo Therapeutics alerts:Sign Up Key Stats Today's Range$0.45▼$0.4750-Day Range$0.44▼$0.8752-Week Range$0.30▼$3.18Volume2.13 million shsAverage Volume8.76 million shsMarket Capitalization$106.72 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingModerate Buy Company OverviewSangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.Read More… Sangamo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreSGMO MarketRank™: Sangamo Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 741st out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingSangamo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageSangamo Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Sangamo Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sangamo Therapeutics are expected to grow in the coming year, from ($0.46) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sangamo Therapeutics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sangamo Therapeutics is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSangamo Therapeutics has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Sangamo Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.73% of the float of Sangamo Therapeutics has been sold short.Short Interest Ratio / Days to CoverSangamo Therapeutics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Sangamo Therapeutics has recently increased by 12.96%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSangamo Therapeutics does not currently pay a dividend.Dividend GrowthSangamo Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.73% of the float of Sangamo Therapeutics has been sold short.Short Interest Ratio / Days to CoverSangamo Therapeutics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Sangamo Therapeutics has recently increased by 12.96%, indicating that investor sentiment is decreasing significantly. News and Social Media2.1 / 5News Sentiment0.86 News SentimentSangamo Therapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Sangamo Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for SGMO on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Sangamo Therapeutics is held by insiders.Percentage Held by Institutions56.93% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sangamo Therapeutics' insider trading history. Receive SGMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SGMO Stock News HeadlinesSangamo Therapeutics (NASDAQ:SGMO) Now Covered by Analysts at Wall Street ZenMay 24, 2025 | americanbankingnews.comSangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.May 29, 2025 | Colonial Metals (Ad)Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same DayMay 12, 2025 | finance.yahoo.comSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial ResultsMay 12, 2025 | businesswire.comSangamo Therapeutics Announces Pricing of $23.0 Million Underwritten OfferingMay 12, 2025 | businesswire.comSangamo Therapeutics Q1 2025 Earnings PreviewMay 12, 2025 | msn.comSangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry DiseaseMay 7, 2025 | finance.yahoo.comSee More Headlines SGMO Stock Analysis - Frequently Asked Questions How have SGMO shares performed this year? Sangamo Therapeutics' stock was trading at $1.02 at the start of the year. Since then, SGMO shares have decreased by 55.1% and is now trading at $0.4577. View the best growth stocks for 2025 here. How were Sangamo Therapeutics' earnings last quarter? Sangamo Therapeutics, Inc. (NASDAQ:SGMO) announced its quarterly earnings results on Monday, May, 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.03. The biopharmaceutical company had revenue of $6.44 million for the quarter, compared to analyst estimates of $7.90 million. Sangamo Therapeutics had a negative trailing twelve-month return on equity of 264.16% and a negative net margin of 257.87%. Read the conference call transcript. Who are Sangamo Therapeutics' major shareholders? Sangamo Therapeutics' top institutional shareholders include Jacobs Levy Equity Management Inc. (0.57%), Charles Schwab Investment Management Inc. (0.48%), GSA Capital Partners LLP (0.42%) and Goldman Sachs Group Inc. (0.42%). Insiders that own company stock include Biogen Inc and John Markels. View institutional ownership trends. How do I buy shares of Sangamo Therapeutics? Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sangamo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Intel (INTC), MSP Recovery (LIFW), MSP Recovery (LIFW) and Abrdn Asia-Pacific Income Fund (FAX). Company Calendar Last Earnings5/12/2025Today5/29/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:SGMO CIK1001233 Webwww.sangamo.com Phone(510) 970-6000Fax510-236-8951Employees480Year Founded1995Price Target and Rating Average Stock Price Target$4.50 High Stock Price Target$10.00 Low Stock Price Target$2.00 Potential Upside/Downside+883.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$257.83 million Net Margins-257.87% Pretax Margin-257.89% Return on Equity-264.16% Return on Assets-107.24% Debt Debt-to-Equity RatioN/A Current Ratio1.35 Quick Ratio1.35 Sales & Book Value Annual Sales$63.76 million Price / Sales1.67 Cash Flow$0.02 per share Price / Cash Flow30.42 Book Value$0.47 per share Price / Book0.97Miscellaneous Outstanding Shares233,167,000Free Float202,805,000Market Cap$106.72 million OptionableOptionable Beta1.46 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:SGMO) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.